2465 related articles for article (PubMed ID: 33055231)
1. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
Williamson BN; Feldmann F; Schwarz B; Meade-White K; Porter DP; Schulz J; van Doremalen N; Leighton I; Yinda CK; Pérez-Pérez L; Okumura A; Lovaglio J; Hanley PW; Saturday G; Bosio CM; Anzick S; Barbian K; Cihlar T; Martens C; Scott DP; Munster VJ; de Wit E
Nature; 2020 Sep; 585(7824):273-276. PubMed ID: 32516797
[TBL] [Abstract][Full Text] [Related]
3. Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.
Jorgensen SCJ; Kebriaei R; Dresser LD
Pharmacotherapy; 2020 Jul; 40(7):659-671. PubMed ID: 32446287
[TBL] [Abstract][Full Text] [Related]
4. A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.
Hashemian SM; Farhadi T; Velayati AA
Drug Des Devel Ther; 2020; 14():3215-3222. PubMed ID: 32821086
[TBL] [Abstract][Full Text] [Related]
5. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
6. Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2.
Dobrovolny HM
Virology; 2020 Nov; 550():61-69. PubMed ID: 32882638
[TBL] [Abstract][Full Text] [Related]
7. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
8. A Review of Remdesivir for COVID-19: Data to Date.
Mehta M; Shyh GI
Cardiol Rev; 2020; 28(6):332-334. PubMed ID: 32773440
[TBL] [Abstract][Full Text] [Related]
9. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H
Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457
[TBL] [Abstract][Full Text] [Related]
10. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
Wooding DJ; Bach H
Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
[TBL] [Abstract][Full Text] [Related]
11. Overview of lethal human coronaviruses.
Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
[TBL] [Abstract][Full Text] [Related]
12. A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.
Liang C; Tian L; Liu Y; Hui N; Qiao G; Li H; Shi Z; Tang Y; Zhang D; Xie X; Zhao X
Eur J Med Chem; 2020 Sep; 201():112527. PubMed ID: 32563812
[TBL] [Abstract][Full Text] [Related]
13. Remdesivir: First Approval.
Lamb YN
Drugs; 2020 Sep; 80(13):1355-1363. PubMed ID: 32870481
[TBL] [Abstract][Full Text] [Related]
14. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence.
Cao YC; Deng QX; Dai SX
Travel Med Infect Dis; 2020; 35():101647. PubMed ID: 32247927
[TBL] [Abstract][Full Text] [Related]
15. Case report study of the first five COVID-19 patients treated with remdesivir in France.
Dubert M; Visseaux B; Isernia V; Bouadma L; Deconinck L; Patrier J; Wicky PH; Le Pluart D; Kramer L; Rioux C; Le Hingrat Q; Houhou-Fidouh N; Yazdanpanah Y; Ghosn J; Lescure FX
Int J Infect Dis; 2020 Sep; 98():290-293. PubMed ID: 32619764
[TBL] [Abstract][Full Text] [Related]
16. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
[TBL] [Abstract][Full Text] [Related]
17. Current pharmacological treatments for SARS-COV-2: A narrative review.
Nittari G; Pallotta G; Amenta F; Tayebati SK
Eur J Pharmacol; 2020 Sep; 882():173328. PubMed ID: 32603692
[TBL] [Abstract][Full Text] [Related]
18. Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2
Weston S; Coleman CM; Haupt R; Logue J; Matthews K; Li Y; Reyes HM; Weiss SR; Frieman MB
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817221
[TBL] [Abstract][Full Text] [Related]
19. The Potential of Algal Biotechnology to Produce Antiviral Compounds and Biopharmaceuticals.
Rosales-Mendoza S; García-Silva I; González-Ortega O; Sandoval-Vargas JM; Malla A; Vimolmangkang S
Molecules; 2020 Sep; 25(18):. PubMed ID: 32899754
[TBL] [Abstract][Full Text] [Related]
20. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2020; 14(4):641-648. PubMed ID: 32428865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]